VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

7 A EGIS C APITAL C ORP. Fig. 4. PH94B Phase 2 results Source: VistaGen, American Journal of Psychiatry In a Phase 2 (randomized, double-blind, placebo-controlled) trial, PH94B was more effective than placebo in reducing public-speaking (p=0.002) and social-interaction anxiety (p=0.009). This was assessed in patients with SAD, using Subjective Units of Distress (SUDS) scoring, with the challenges coming within 15-minutes of self-administration of 1.6 microgram doses of PH94B. VistaGen Therapeutics, Inc. October 8, 2020